Nemaura Medical Inc (NMRD)
Nemaura Medical Inc. is a healthcare equipment and supplies company focused on medical technology and continuous glucose monitoring. The company develops and manufactures its continuous glucose monitoring system in the United States, including sugarBEAT, a non-invasive device designed for people with Type I and Type II diabetes and for pre-diabetic screening. It also provides proBEAT, a wellness guidance tool that delivers prompts and educational support related to factors that can influence blood sugar levels. In addition, Nemaura Medical conducts programs aimed at diabetes prevention and reversal. Founded in 2009, the company is based in New York, New York, and its common stock trades on OTC Markets under the symbol NMRD.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-NMRD
|
—
|
—
|
—
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
—
|
—
|
—
|
4.035 K
|
—
|
—
|
—
|
—
|
—
|
—
|